单胺氧化酶抑制剂在临床方面的应用

单胺氧化酶（monoamine oxidase, MAO）是人体内天然存在的一种酶,催化单胺类物质氧化脱氨反应的酶。人体内含有两种单胺氧化酶：单胺氧化酶A 和单胺氧化酶B。单胺氧化酶A 主要分布在儿茶酚胺能神经元中;单胺氧化酶B 主要分布在5- 羟色胺能神经元、组胺能神经元和神经胶质细胞中,这两种亚型都均可以使单胺类神经递质失活。而单胺氧化酶抑制剂则能够通过抑制单胺氧化酶的对单胺类物质的氧化活性,从而达到减轻或者消除由各种原因引起的单胺类物质减少或单胺氧化酶活性过高导致的疾病。本文主要总结了近几年单胺氧化酶抑制剂在临床上用于治疗帕金森病、抑郁症和幽门螺旋杆菌方面的最新进展。     

干酪乳杆菌JH-23中单胺氧化酶抑制剂的初步分离

采用丙酮抽提法得到了干酪乳杆菌JH-23中具有抑制单胺氧化酶作用的无细胞提取物,并利用硅胶薄层色谱从中分离出4组活性片段,其中片段Ⅰ对单胺氧化酶的抑制效果最佳,反应浓度在120μg/mL时抑制率为55.4%。该活性片段经国家新药筛选中心确证有抑制单胺氧化酶的效果,具有潜在的抗衰老作用。     

单胺氧化酶

单胺氧化酶（monoamine oxidase,MAO）是生物体内一种十分重要的酶,它在大脑和周围神经组织中催化一些生物体产生的胺,氧化脱氨产生过氧化氢（H₂O₂）.单胺氧化酶A和B基因的克隆清楚地证明了这些酶是由不同的多肽组成的.单胺氧化酶A和B的基因定位于X染色体（Xp11.23）,都由15个外显子组成,而且它们的内含子-外显子组织是完全一致的.这些事实表明单胺氧化酶A和B的基因很可能从同一个祖先进化而来.单胺氧化酶A和B具有不同的底物和抑制剂专一性,在生物神经递质代谢和行为方面具有不同的作用.     

随机突变提高单胺氧化酶活性

前期获得了一个对底物美西律具有一定活性的单胺氧化酶突变体A-1(F210V/L213C)。为进一步提高其酶活性,利用MegaWHOP PCR构建了库容约为104的随机突变库。筛选后获得了一个最优突变酶ep-1,比活力为A-1的189%。选择性测定结果表明,酶的对映体选择性有较大提高,E值由101提高到282;动力学常数测定揭示,酶催化效率有较大提高,kcat/Km由0.001 51 mmol/(L?s)提高到0.002 89 mmol/(L?s)。和A-1酶相比,在所测定的11种胺类底物中,ep-1对其他7种底物的比活力有较明显提高,对其他4种底物的比活力变化不大。序列分析表明,ep-1的突变为T162A。分子动力学模拟结果提示,该突变主要通过修正通道氨基酸的二级结构和扩大活性口袋来发挥作用。     

尿嘧啶对单胺氧化酶的抑制作用

给青年小鼠(1月龄)po尿嘧啶25—800mg/kg对脑和肝MAO-B活性抑制作用与剂量成明显量-效关系,而对MAO-A抑制较弱。多次po尿嘧啶300mg/kg对老年小鼠(18月龄)脑MAO活性抑制作用明显强于对青年小鼠,并能增加老年小鼠脑组织5-HT和DA含量。另外,随年龄增加,小鼠血、脑和肝组织MAO活性显著升高,而上述组织中尿嘧啶含量则明显降低。体外实经证明,尿嘧啶对MAO-B活性抑制程度明显强子对MAO-A,并且对MAO-B为竞争性抑制,对MAO-A为混合型抑制。     

老龄大鼠心肌单胺氧化酶的研究

本文比较研究了年轻鼠和老龄鼠心肌线粒体MAO的活力变化,及MAO活力对温度的依赖性。结果表示老龄心肌MAO对底物的亲合性略有下降,但酶活力增加了近十倍。在12—43℃范围内绘制的MAO活力的Arrhenius图提示老龄鼠线粒体膜脂的物理性状发生了改变。     

大豆磷脂对老龄大鼠单胺氧化酶,血小板,动脉内膜的影响

本文观察了饲料添加剂大豆磷脂对老龄大鼠脑组织单胺氧化酶(MAO)活力、血小板聚集功能及主动脉内膜的影响。结果表示喂大豆磷脂24月龄大鼠组的大脑皮层、小脑、海马的MAO活力较对照组高,接近3月龄组;二磷酸腺苷(ADP)诱导血小板释放三磷酸腺苷(ATP)的量高于3月龄组,低于对照组;主动脉内膜扫描电镜观察内皮细胞轮廓清晰可见,有少数桥样结构,表面未见斑块样附着物,对照组则呈粥样硬化形态特征。上述结果提示,大豆磷脂作为饲料添加剂对某些衰老现象有明显的改善。     

不同菌株白僵菌代谢产物对大鼠肝线粒体单胺氧化酶的抑制作用研究

对8株白僵菌[Beauveriasp.]代谢产物的抑制单胺氧化酶的活性进行测定,发现菌株Ba02和Ba05的乙酸乙酯提取物在终浓度为55μg/mL时,对单胺氧化酶A型(MAO＿＿A)有较强的抑制活性,其抑制率分别为95.9%和83.4%;Ba02及Ba03菌株脂溶性成分在终浓度为55μg/mL时对单胺氧化酶B型(MAO＿B)有较强的抑制活性,其抑制率分别为94.8%和84.1%。浓度和抑制活性关系研究表明在一定浓度范围内Ba02菌株脂溶性成分对MAO的抑制活性呈量效关系,经计算得出其对MAO＿A、MAO＿B抑制的IC50分别为18.3μg/mL、28.2μg/mL;抑制特征曲线表明Ba02菌株脂溶性成分对MAO＿A呈竞争型抑制,对MAO＿B为混合型抑制,Km值分别为0.47×10-5mol/L,0.11×10-5mol/L。     

血清单胺氧化酶遗传特性的初步研究

通过采用卵性鉴定准确性在98%以上的双生子法对22对单卵双生子及16对双卵双生子进行血清 MAO活性的遗传研究，结果发现单卵双生子对的血清MAO活性相关系数达。.67，而双卵双生子对 的血清MAO活性相关系数仅0.18,说明遗传因素对血清MAO活性的大小起有一定作用。用三种方法 计算其遗传度为60-98%ao     

A Caution in the Use of Tritiated Substrates for Monoamine Oxidase Assays

Abstract: A monoamine oxidase assay utilizing generally labeled [³H]-serotonin as substrate became nonlinear after only ～5% conversion of initial c.p.m. to product. Subsequent analysis showed that a significant proportion of the tritium label was readily exchangeable into water and that monoamine oxidase activity increased release of label as water. The use of generally labeled substrates for oxidase activities is not recommended.     

幽门螺杆菌根除治疗对帕金森病患者运动症状的影响

目的:探讨幽门螺杆菌(HP)根除治疗对帕金森病(PD)患者运动症状的影响及其安全性,为临床治疗提供参考。方法:选取2013年1月-2015年10月医院收治的PD患者120例,根据尿素呼吸试验(UBT)检测结果,将PD患者分为HP组(n=32)和非HP组(n=88),两组均进行抗PD的常规治疗,HP组在此基础上采用HP根除治疗(奥美拉唑+克拉霉素+阿莫西林),采用帕金森病评定量表(UPDRS)评估两组患者治疗前后的运动症状,并对治疗过程中的不良反应进行统计分析。结果:120例PD患者中,HP感染32例占26.67%,经HP根除治疗后,HP检测阴性者26人,成功根除率81.25%。组间比较,治疗前两组UPDRS Ⅳ评分有统计学差异(P0.05),而UPDRS Ⅲ评分、Hoehn-Yahr分级、"开"期和"关"期时间无统计学差异(P0.05);治疗后两组"开"期和"关"期时间存在统计学差异(P0.05),而UPDRS Ⅲ评分、UPDRS Ⅳ评分、Hoehn-Yahr分级无统计学差异(P0.05)。组内比较,治疗后,HP组UPDRS Ⅲ评分和UPDRS Ⅳ评分均较治疗前下降,差异有统计学意义(P0.05),且"开"期时间明显延长,"关"期时间明显缩短,差异均有统计学意义(P0.05),而非HP组治疗前后上述各项指标比较,差异均无统计学意义(P0.05)。HP根除组不良反应发生率与非HP组相比,差异无统计学意义(P0.05)。结论:HP感染与PD的发生有关,HP根除治疗能显著改善PD患者的运动症状,安全有效,值得临床推广使用。     

Inhibition of Monoamine Oxidase by N-Methylisoquinolinium Ion

N-Methylisoquinolinium ion (N-MIQ) has been found to inhibit the biosynthesis of catecholamines; it inhibited tyrosine hydroxylase activity in striatal tissue slices. In this article, the effects of N-MIQ and an analogue, N-methylquinolinium ion, on monoamine oxidase (MAO) activity were examined to see their effects on the catabolism of catecholamines. MAO-A in human placental mitochondria was strongly inhibited by N-MIQ in competition with the substrate. The apparent Ki value of N-MIQ was found to be 20.4 +/- 1.1 microM, whereas that of N-methylquinolinium ion was 54.6 +/- 4.5 microM. MAO-B in human brain synaptosomes and liver mitochondria was found to be inhibited by N-MIQ, but the inhibition proved to be noncompetitive. The inhibition of MAO-B by N-MIQ was completely reversible by dialysis of the incubation mixture. MAO-A in human brain and liver mitochondria was more sensitive to the inhibitor than MAO-B. By quantitative analysis of N-MIQ, using HPLC, it was found not to be catabolized by the incubation with mitochondria, suggesting that the inhibition was due to N-MIQ itself and not due to any metabolic product. The inhibition of MAO by N-MIQ is discussed in terms of its possible involvement of the etiology of parkinsonism.     

Oxidation of β-Phenylethylamine by Both Types of Monoamine Oxidase: Examination of Enzymes in Brain and Liver Mitochondria of Eight Species

Abstract: β-Phenylethylamine (PEA) was characterized as a substrate for type A and type B monoamine oxidase (MAO) in brain and liver mitochondria of eight species at different substrate concentrations. In all species, at 10.0 μM, PEA was almost specific for type B MAO. At 1000 μM, however, the amine was common for both types of MAO in rat brain and liver, human brain and liver, mouse brain, guinea pig brain and liver, and bovine brain, while it was specific for type B MAO in mouse liver, rabbit brain and liver, bovine liver, pig brain and liver, and chicken brain and liver. From the present study, when PEA is used as a type B substrate, it is recommended that the substrate concentration should be sufficiently low to avoid the effects of species and tissue differences.     

Inhibition of Monoamine Oxidase by 7-Chloro-4-Nitrobenzofurazan

7-Chloro-4-nitrobenzofurazan (NBD-Cl) is a potent inhibitor of both types of monoamine oxidase (MAO). NBD-Cl competitively inhibited the oxidative deamination of kynuramine catalyzed by human placenta MAO-A, the oxidative deamination of benzylamine catalyzed by bovine liver MAO-B, the oxidative deamination of serotonin catalyzed by rat brain MAO-A, and the oxidative deamination of phenylethylamine catalyzed by rat brain MAO-B. In addition, a time-dependent inactivation of MAOs by NBD-Cl has been demonstrated upon incubation of the enzyme preparations with NBD-Cl at pH 9, but not at pH 7.5. The time-dependent inhibition of MAO by NBD-Cl could be prevented by the addition of 4-nitrophenyl azide, an active site-directed label of MAO, during incubation of the enzyme with NBD-Cl. On the basis of these findings, it is suggested that at pH 9, NBD-Cl modifies one (or more) essential lysine residue(s) in the active sites of the two types of MAO.     

Metabolism of Monoamine Oxidase Inhibitors

1. The principal routes of metabolism of the following monoamine oxidase inhibitors (MAOIs) are described: phenelzine, tranylcypromine, pargyline, deprenyl, moclobemide, and brofaromine.2. Acetylation of phenelzine appears to be a minor metabolic pathway. Phenelzine is a substrate as well as an inhibitor of MAO, and major identified metabolites of phenelzine include phenylacetic acid and p-hydroxyphenylacetic acid. Phenelzine also elevates brain GABA levels, and as yet unidentified metabolites of phenelzine may be responsible for this effect. -Phenylethylamine is a metabolite of phenelzine, and there is indirect evidence that phenelzine may also be ring-hydroxylated and N-methylated.3. Tranylcypromine is ring-hydroxylated and N-acetylated. There is considerable debate about whether or not it is metabolized to amphetamine, with most of studies in the literature indicating that this does not occur.4. Pargyline and R(–)-deprenyl, both propargylamines, are N-demethylated and N-depropargylated to yield arylalkylamines (benzylamine, N-methylbenzylamine, and N-propargylbenzylamine in the case of pargyline and amphetamine, N-methylamphetamine and N-propargylamphetamine in the case of deprenyl). These metabolites may then undergo further metabolism, e.g., hydroxylation.5. Moclobemide is biotransformed by C- and N-oxidation on the morpholine ring and by aromatic hydroxylation. An active metabolite of brofaromine is formed by O-demethylation. It has been proposed that another as yet unidentified active metabolite may also be formed in vivo. 6. Preliminary results indicate that several of the MAOIs mentioned above are substrates and/or inhibitors of various cytochrome P450 (CYP) enzymes, which may result in pharmacokinetic interactions with some coadministered drugs.     

Inhibition of Monoamine Oxidase by 3,4-Dihydroxyphenylserine

The effects of diastereomers of 3,4-dihydroxyphenylserine (DOPS) on the enzyme activity of monoamine oxidase (MAO) in human placenta and liver mitochondria were examined. Both L- and D-threo-DOPS were found to inhibit MAO-A in human placental mitochondria in competition with the substrate, and the Ki values for L- and D-threo-DOPS obtained were 68.3 and 125 microM, respectively. The inhibitory effect of L-threo-DOPS on both MAO-A and -B activity was confirmed in human liver mitochondria, and MAO-A was found to be more sensitive to the inhibitor. Other isomers of DOPS, L- and D-erythro-DOPS, were found to inhibit MAO activity, but the inhibition was noncompetitive with the substrate. The inhibitory effects of DOPS isomers were not affected by the presence of NSD-1055, an inhibitor of aromatic L-amino acid decarboxylase, suggesting that the inhibition is the direct effect of DOPS, and not of norepinephrine produced by the decarboxylase.     

Inhibition of Monoamine Oxidase by Phenyl Azides

We had previously shown that 4-fluoro-3-nitrophenyl azide (FNPA) is a competitive inhibitor of both types of monoamine oxidase (MAO) in the dark, but it is a preferential photoaffinity label for only the type B MAO (MAO-B). Recently we synthesized a number of arylazido compounds with structures related to FNPA and determined the effects of these compounds on the two types of MAO in rat brain cortex. We found that the fluoro group of FNPA was not required for the inhibition of MAO activities because neither the presence nor the position of the fluoro group affected its inhibition of MAO. On the other hand, both the nitro and the azido groups of FNPA were shown to be important for FNPA inactivation of two types of MAO. The inhibitory potency was significantly lower for compounds without either group. Furthermore, we found that all nitrophenyl azide isomers except 2-nitrophenyl azide were photodependent inhibitors of MAO-B. Under the same experimental conditions none of the compounds photoinactivated MAO-A. On the basis of these findings, mechanisms for FNPA inhibition of the two types of MAO are discussed.